Please assess the completion status of the following clinical trial:

Trial Title: Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed B-cell non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and other B-cell lymphoproliferative disorders as approved by the Medical Monitor or Study Chair~* Refractory to or relapsed after at least 1 prior treatment regimen~* Eastern Cooperative Oncology Group (ECOG) score of 0 to 2~Exclusion Criteria:~* Any major surgery, chemotherapy or immunotherapy within the last 21 days~* Known hepatitis B virus, hepatitis C virus or HIV infection~* Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months~* Primary central nervous system lymphoma or known intracranial involvement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ublituximab + TGR-1202 (Type: EXPERIMENTAL): Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose
- Ublituximab + TGR-1202 + ibrutinib (Type: EXPERIMENTAL): Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose ibrutinib oral daily dose
- Ublituximab + TGR-1202 + bendamustine (Type: EXPERIMENTAL): Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Bendamustine at a fixed IV infusion on Days 1 \& 2

Based on this trial design, predict the completion outcome and termination type (if applicable).